Biosense Technologies
Stage
Dead | DeadTotal Raised
$530KAbout Biosense Technologies
BioSense Technologies proposes the development of a new phenotypic assay for determining antibiotic minimum inhibitory concentrations (MIC) in 60 minutes. The technology monitors the development of antibiotic-induced cellular stress as an early response for determining the effect of therapeutic agents on cellular suspensions. The immediacy and ubiquity of the response enables near real-time assessment of all bacterial species treated with drugs having different mechanisms of action.
Missing: Biosense Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Biosense Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Biosense Technologies Patents
Biosense Technologies has filed 12 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/11/2007 | 1/29/2013 | Small nuclear RNA, Transcription factors, Cell biology, Molecular biology, Biotechnology | Grant |
Application Date | 1/11/2007 |
|---|---|
Grant Date | 1/29/2013 |
Title | |
Related Topics | Small nuclear RNA, Transcription factors, Cell biology, Molecular biology, Biotechnology |
Status | Grant |
Latest Biosense Technologies News
Dec 6, 2019
VCCircle Indian Institute of Management, Ahmedabad’s startup incubator CIIE.Co has profitably exited its first health-tech investment. Mumbai-based Biosense Technologies, a diagnostics device maker has been acquired by Bengaluru-based in-vitro, kits and instruments provider Tulip Diagnostics. The terms of the deal were not disclosed. Tulip has a footprint in 70 countries across the world. Biosense was founded by Abhishek Sen, Yogesh Patil, Myshkin Ingawale, and Aman Midha and incubated by CIIE.Co a decade ago. Its devices are focussed on the detection and screening of conditions such as diabetes, anaemia and malnutrition. “The returns that we receive through this exit will be ploughed back to support more med-tech startups and entrepreneurs in the coming years. This exit also is an indicator that early-stage investments can be profitable and India has the potential to build medical device companies for global acquisitions,” Vipul Patel, partner, seed investing, at CIIE.Co, said. After being incubated at CIIE.Co, Insitor Fund, Menterra Social Impact Fund, The Lemelson Foundation and The Netri Foundation supported Biosense in various capacities, as per the statement. Prior to the acquisition, Biosense had raised at least $3.34 million in disclosed investment rounds according to data compiled by VCCEdge. CIIE.CO helps startups not only with incubation but also in terms of investments and acceleration programmes. It provides infrastructure, training, and access to a network of collaborators. Other startups in the med-tech space in CIIE.Co’s portfolio include Crimson Health, Rcupe Life Sciences, OnwardAI, and iNICU, and Green Ocean Research Labs. Tags
Biosense Technologies Frequently Asked Questions (FAQ)
Where is Biosense Technologies's headquarters?
Biosense Technologies's headquarters is located at 4 Arrow Drive, Woburn.
What is Biosense Technologies's latest funding round?
Biosense Technologies's latest funding round is Dead.
How much did Biosense Technologies raise?
Biosense Technologies raised a total of $530K.
Who are the investors of Biosense Technologies?
Investors of Biosense Technologies include National Science Foundation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.